We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Supreme Court is seeking advice from the U.S. government on whether it should review a federal antitrust lawsuit triggered by a reverse-payment deal that delayed the launch of generic tamoxifen.